Precipio Inc Stock Price, News & Analysis

Precipio (NASDAQ: PRPO) has announced that the American Oncology Network (AON) has validated and will adopt its proprietary IV-Cell® culture media for use in clinical cytogenetics laboratories. This marks a significant step in Precipio's strategic business model as a specialty cancer diagnostics company, showcasing its ability to address unmet market needs with innovative products. AON's adoption of IV-Cell follows its previous launch of HemeScreen® testing with Precipio, highlighting cross-selling potential and operational efficiencies aimed at enhancing diagnostic accuracy.

Precipio, a specialty cancer diagnostics company, announced its participation in the Executive War College, taking place from April 26-28, 2022, in New Orleans. The company's innovative diagnostic platform, HemeScreen, was selected for presentation to laboratory executives. This endorsement showcases the technology's potential to improve clinical outcomes and laboratory efficiency. The presentation will occur on April 27 at 1:45 PM, with management available for discussions. CEO Ilan Danieli highlighted the importance of HemeScreen in enhancing diagnostic accuracy and patient care.

Precipio, Inc. (NASDAQ: PRPO) will host its Q4-2021 and year-end shareholder update call on April 4th, 2022, at 5:00 PM ET. This call aims to provide updates on the company’s core businesses. Interested participants can access the call by dialing 844-695-5519 or registering online for a direct dial-in number. Questions can be submitted in advance via email. A replay will be available on Precipio's investors page approximately 24 hours post-call. Precipio focuses on improving diagnostic accuracy in cancer treatment.

Precipio (NASDAQ: PRPO) announces the resignation of CFO Carl Iberger, effective March 21, 2022, citing family time as the reason. Matt Gage, the current Director of Financial Reporting and Analysis, has been appointed as the Interim CFO. Gage, with over 30 years of finance experience, including 25 years in publicly traded companies, is expected to ensure a smooth transition. The leadership change comes as Iberger reflects on a successful six-year tenure, emphasizing a positive outlook for Gage's contribution to the company's financial management.

Precipio (NASDAQ: PRPO) reported a 45% increase in revenues for 2021, totaling $8.9 million, driven primarily by pathology diagnostic testing. Q4 revenues reached $2.4 million, a 25% rise from the previous year. The HemeScreen product line is expected to contribute to further growth, with annualized contracts exceeding $1.6 million. Despite challenges from COVID-19, the company is optimistic about 2022, predicting significant revenue growth across its diagnostics segment, aiming to reduce cash burn and improve financial stability.

Precipio, Inc. (NASDAQ: PRPO) has announced that its HemeScreen RUO assay has received approval from the New York State Department of Health (NY DOH). This allows physician-owned laboratories (POLs) in New York to apply to run HemeScreen as a laboratory-developed test (LDT). The first customer, New York Cancer & Blood Specialists, estimates a potential for seven-figure revenues from HemeScreen, along with a Florida-based customer also utilizing the assay. This marks a significant milestone for Precipio, enhancing its market presence and potentially reducing cash burn.

Precipio, a specialty cancer diagnostics company (NASDAQ: PRPO), will host its Q3-2021 update conference call on November 15, 2021, at 5:00 PM ET. The call aims to provide updates on the company’s core businesses and can be accessed by calling 844-695-5519 or through pre-registration at their website. Precipio collaborates with renowned institutions like Yale and Dana-Farber to improve diagnostic accuracy in cancer care. Replay access will be available 24 hours post-call via their Investors page.

Precipio, Inc. (NASDAQ: PRPO) has signed a multi-year agreement with American Oncology Network (AON) to implement HemeScreen technology in AON's laboratory in Fort Myers, Florida. This partnership allows AON, the largest Physician Owned Laboratory, to reduce diagnostic turnaround times from 2-4 weeks to 1-4 days, significantly improving patient care. The deal is expected to generate seven-figure annual revenue for Precipio.

Both companies aim to enhance oncology diagnostics, with AON serving around 100,000 patients annually.

Precipio, Inc. (NASDAQ: PRPO) has rescheduled its Q2 2021 update call from August 23 to August 26 at 5:00 PM ET due to a scheduling conflict. Interested participants can access the call by calling 844-695-5519 or registering in advance for a direct dial-in number. The call will allow for pre-submitted questions via email. A replay will be available 24 hours post-call on Precipio's investors page.

Precipio focuses on enhancing diagnostic accuracy through collaborations with esteemed cancer research institutions.